The Single English County Saying No to Palantir
Greater Manchester, an English county, has refused to adopt Palantir's national Federated Data Platform (FDP) for the NHS, opting instead for its homegrown system, sparking a national debate over the £480 million contract.
Intelligence analysis by Gemini 2.5 Flash
The UK's National Health Service (NHS) is rolling out a data platform developed by American software company Palantir, aimed at integrating health data across the country. However, Greater Manchester has resisted, claiming its existing local platform is superior and more trusted by the public, fueling calls for the government to terminate the controversial contract early.
Imagine the doctors and nurses in a big hospital trying to keep track of all their patients using different notebooks, sticky notes, and old computers. It's messy! A company called Palantir offered to build a super-smart digital system to put all that information in one place, like a giant, organized digital filing cabinet, to help everyone work better. But one big area in England, called Greater Manchester, said, "No thanks! We already built our own awesome system over many years, and people here trust it more." Now, everyone is wondering if the whole country should stick with Palantir's system or if they should follow Greater Manchester's lead and use their own ideas.
Analysis
The decision by Greater Manchester to reject Palantir's Federated Data Platform (FDP) for the NHS underscores a significant challenge in large-scale public sector technology adoption: balancing national standardization with local innovation and public trust. The county's steadfast refusal, despite national pressure, brings into sharp focus the complexities of integrating disparate health data systems while navigating concerns about data sovereignty and the role of private, often controversial, tech firms in critical public infrastructure. This localized resistance has amplified a broader national conversation about the £480 million contract, prompting parliamentary inquiries and calls for its early termination.
Greater Manchester
Greater Manchester stands as the sole English region whose Integrated Care Board (ICB) has categorically declined to implement Palantir's FDP. Instead, the region, which serves approximately 3 million people, continues to rely on its internally developed Analytics and Data Science Platform (ADSP). Officials from NHS Greater Manchester assert that their ADSP not only meets but exceeds the functionalities offered by Palantir's system, claiming it is two to three years ahead in certain capabilities. The ADSP's modular design allows for easier component upgrades, such as swapping out data visualization software, which is cited as a key advantage over a monolithic external platform. Crucially, the ADSP has cultivated deep public trust over many years, which is vital for encouraging the sharing of sensitive health data necessary for such platforms to operate effectively.
Palantir's FDP
Palantir's Federated Data Platform was commissioned in 2023 with the ambitious goal of organizing and integrating the vast and often fragmented health data across the UK's NHS. The platform is designed to create a national pool of health data for identifying care deficiencies, alongside local databases for regional analyses and tool development, such as waitlist management. Advocates, including Palantir and NHS England, claim the FDP is already demonstrating tangible benefits, such as reducing wait times, shortening hospital stays, and optimizing operating theatre usage. The underlying technology scaffolding is intended to facilitate the easy transfer and adoption of tools developed in one region across the entire country, creating a unified ecosystem for data-driven healthcare improvements. Furthermore, the FDP is touted as providing a robust foundation for the application of artificial intelligence across NHS data.
NHS Contract
The NHS contract with Palantir, valued at over $400 million, has become a significant point of contention. The UK government faces a critical decision point in six months regarding whether to exercise an option to terminate the deal early, rather than allowing it to run until 2031. The resistance from Greater Manchester, coupled with broader concerns about Palantir's involvement in military and immigration enforcement contexts, has intensified scrutiny. Critics argue that if one major region can successfully operate without Palantir, the entire NHS could potentially do the same, leveraging homegrown solutions or alternative providers. This debate extends beyond the immediate contract, touching on wider European anxieties about dependence on US-made technology, particularly in sensitive sectors like healthcare, and the imperative to maintain data sovereignty and public confidence in national digital infrastructure.
Key points
- Greater Manchester has refused to adopt Palantir's Federated Data Platform (FDP) for the NHS, preferring its homegrown Analytics and Data Science Platform (ADSP).
- The UK government has six months to decide whether to terminate its £480 million contract with Palantir early, which is currently set to run until 2031.
- Palantir's FDP aims to integrate health data across the NHS to improve efficiency, cut wait times, and optimize hospital operations.
- Greater Manchester claims its ADSP is functionally superior, more easily reconfigurable, and benefits from deeper public trust.
- The debate highlights broader concerns about public trust in private tech companies handling sensitive data and Europe's dependence on US-made technology.
If the FDP or similar integrated data platforms are successfully implemented, they could significantly improve patient care by enabling better resource allocation, reducing wait times, and facilitating data-driven medical decisions across the NHS. Greater Manchester's success with its ADSP also demonstrates the potential for local innovation to create trusted and effective solutions, offering a model for other regions or even national adoption.
Continued fragmentation in data systems, with some regions using Palantir and others their own platforms, could hinder the NHS's ability to achieve comprehensive data integration and consistent patient care improvements. Furthermore, reliance on a single, controversial private company for critical national health infrastructure could erode public trust and raise concerns about data privacy and sovereignty.
